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Abstract
Background The role of laparoscopic surgery in man-
agement of transverse and descending colon cancer
remains controversial. The aim of the present study is to
investigate the short-term and oncologic long-term out-
comes associated with laparoscopic surgery for transverse
and descending colon cancer.
Methods This cohort study analyzed 245 patients (stage II
disease, n = 70; stage III disease, n = 63) who underwent
resection of transverse and descending colon cancers,
including 200 laparoscopic surgeries (LAC) and 45 con-
ventional open surgeries (OC) from December 1996 to
December 2010. Short-term and oncologic long-term out-
comes were recorded.
Results The operative time was longer in the LAC group
than in the OC group. However, intraoperative blood loss
was signiﬁcantly lower and postoperative recovery time
was signiﬁcantly shorter in the LAC group than in the OC
group. The 5-year overall and disease-free survival rates
for patients with stage II were 84.9% and 84.9% in the OC
group and 93.7% and 90.0% in the LAC group, respec-
tively. The 5-year overall and disease-free survival rates for
patients with stage III disease were 63.4% and 54.6% in the
OC group and 66.7% and 56.9% in the LAC group,
respectively.
Conclusion Use of laparoscopic surgery resulted in
acceptable short-term and oncologic outcomes in patients
with advanced transverse and descending colon cancer.
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Since publication of the ﬁrst report of laparoscopic surgery
for colon cancer in 1991 [1], utilization of the procedure
has steadily increased. Beneﬁts of laparoscopic surgery
relative to open surgery include improved cosmesis,
improved short-term outcomes, reduced surgical trauma,
reduced requirements for narcotic analgesia, earlier return
of bowel function, and shorter postoperative hospital stay
[2–4]. However, due to an insufﬁcient body of clinical
evidence, laparoscopic surgery for colon cancer has not yet
replaced the conventional open surgery as the standard of
care.
Although the safety and oncologic efﬁcacy of laparo-
scopic surgery for treatment of colon cancer have been
demonstrated in many randomized controlled trials [5–13],
patients with transverse colon and descending colon cancer
were excluded from many of these trials, mainly due to the
difﬁculty in determining the appropriate operative proce-
dure and the extent of lymphadenectomy [14]. Several
recent studies have described the feasibility and safety of
laparoscopic surgery for transverse and descending colon
cancer [15–19]. However, there are few reports that
describe the long-term outcomes associated with this
management strategy.
In our institution, laparoscopic surgery was performed in
more than 1,000 patients with colon cancer up to December
2008. Thus, the goal of this study is to investigate the short-
term and oncologic long-term outcomes associated with
laparoscopic surgery for transverse and descending colon
cancer.
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and Other Interventional Techniques Patients and methods
The ﬁrst laparoscopic resection for colon cancer at our
institution was performed in 1996. At that time, laparo-
scopic colectomy was indicated only for early-stage cancer.
Gradually, the indication for this procedure was expanded
to more advanced stages of cancer. Further, with stan-
dardization of the surgical system, more than 90% of
colorectal resections were ultimately performed laparo-
scopically. Conversion to conventional open surgery was
performed at surgeon discretion. Between December 1996
and December 2008, 1,236 patients underwent surgery for
colon cancer (laparoscopic surgery, n = 1,009: conven-
tional open surgery, n = 227). Of these, 245 resections
were performed for cancers of the transverse and
descending colon without synchronous double malignan-
cies. All patients underwent comprehensive assessment
with blood testing, serum carcinoembryonic antigen mea-
surement, colonoscopy, pathologic conﬁrmation, barium or
air enema, computed tomography (CT), and chest X-ray
before surgery. If tumor localization was unclear, preop-
erative colonoscopic India ink tattooing and clipping was
performed. The procedure for lymphadenectomy was
determined based on depth of tumor invasion according to
the Japanese Classiﬁcation of Colorectal Carcinoma [20].
The laparoscopic nontouch isolation technique (i.e., the
median-to-lateral approach) was utilized whenever possi-
ble. The study was approved by the institutional ethics of
research committee, and informed consent was obtained
from each patient.
Study design
This cohort study analyzed 245 patients (stage II disease,
n = 70; stage III disease, n = 63) who underwent resec-
tion of the transverse and descending colon cancer,
including 200 laparoscopic surgeries (LAC) and 45 con-
ventional open surgeries (OC) from December 1996 to
December 2010. Short-term outcomes and oncologic long-
term outcomes were assessed among patients with stage II
(70 cases) and stage III (63 cases) disease.
Laparoscopic procedures
For transverse colon lesions, proximal ligations of the right
or left branch or the root of the middle colic vessels were
conducted, and lymphadenectomy was performed simul-
taneously using the median-to-lateral approach. Mobiliza-
tion was performed from the hepatic and/or splenic
ﬂexures. For the hepatic side, if the root of the middle colic
vessels was clearly identiﬁed, the vein was divided just
before the point at which it drained into the gastrocolic
trunk of Henle.
For descending colon lesions, the left branch of the
middle colic, left colic and sigmoid colic pedicles were
identiﬁed, and lymphadenectomy was performed simulta-
neously with proximal ligations of the tumor-feeding ves-
sels. The mesentery of the descending colon was gently
mobilized from the ligament of Treitz by the median-to-
lateral approach. The omental bursa was entered, and the
mesentery of the transverse colon was dissected from the
inferior border of the pancreas. The bowel loop of trans-
verse or descending colon was delivered under a wound
protector through a 3- to 5-cm incision and was divided
from the marginal vessels. The anastomosis was performed
extracorporeally using the functional end-to-end method.
Postoperative follow-up
For follow-up, patients with stage I and II disease under-
went assessment of serum carcinoembryonic antigen levels
(at 3-month intervals during the ﬁrst year and at 6-month
intervals thereafter), chest and abdominopelvic CT (at
6-month intervals), and colonoscopy (at 1-year intervals) in
addition to routine outpatient visits. Patients with stage III
disease underwent assessment of serum carcinoembryonic
antigen levels (at 4-month intervals during the ﬁrst 2 years
and at 6-month intervals thereafter), chest and abdomino-
pelvic CT and colonoscopy at the same interval in addition
to routine outpatient visits. Patients with stage III disease
received adjuvant chemotherapy with 5-ﬂuorouracil plus
leucovorin per standards of care.
Statistical analysis
Statistical analysis was performed using JMP 8 (SAS
Institute Inc., Cary, NC, USA) for Windows. Student’s
t test, Mann–Whitney U test and the v
2 test were used to
compare continuous and categorical variables, respec-
tively, with two-sided p\0.050 indicating signiﬁcance.
Patient survival analysis was performed using Kaplan–
Meier survival curves with log-rank statistics.
Results
Laparoscopic surgery versus conventional open surgery
Patient demographics and pathologic variables are sum-
marized in Table 1. Gender, age, body mass index (BMI),
and American Society of Anesthesiology (ASA) classiﬁ-
cation were not signiﬁcantly different when comparing the
OC group and the LAC group. According to the tumor–
node–metastasis (TNM) classiﬁcation, the proportion of
patients with advanced stage was higher in the OC group
than in the LAC group, mainly because LAC was initially
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123used only for early-stage cancers. Therefore, short-term
outcomes and oncologic long-term outcomes were inves-
tigated in patients with stage II (70 cases) and stage III (63
cases) disease. Patient demographics and pathologic vari-
ables of these cases are summarized in Table 2. Patients
with stage II disease undergoing OC included 3 right
hemicolectomies, 4 left hemicolectomies, and 8 transverse
colectomies, while patients with stage III disease under-
going OC included 1 right hemicolectomy, 6 left colecto-
mies, and 12 transverse colectomies. By contrast, patients
with stage II disease undergoing LAC included 15 right
hemicolectomies, 21 left hemicolectomies, and 19 trans-
verse colectomies, while patients with stage III disease
undergoing LAC included 11 right hemicolectomies, 23
left colectomies, and 10 transverse colectomies. Five
(9.1%) patients with stage II disease required conversion to
open surgery (bleeding, n = 3; surgical technique, n = 1;
massive invasion, n = 1). Six (13.6%) patients with stage
III disease required conversion to open surgery (adhesion,
n = 2; massive invasion, n = 2; bleeding, n = 1; surgical
technique, n = 1). All patients underwent D3 lymphade-
nectomy according to the Japanese Classiﬁcation of
Colorectal Carcinoma [20]. Gender, age, BMI, ASA clas-
siﬁcation, tumor size, number of dissected lymph nodes,
and tumor differentiation were not signiﬁcantly different
when comparing the OC group and the LAC group.
According to the TNM classiﬁcation, the proportion of
patients with pathologic T (pT) category was higher in the
OC group than in the LAC group, likely because of the
exclusion criteria utilized for this study. However, in terms
of pathologic N (pN) category, there was no signiﬁcant
difference between the OC and the LAC group.
Table 3 presents the short-term outcomes of patients
with stage II or stage III disease who underwent OC or
LAC for transverse and descending colon cancer. The
median operative time in patients with stage II disease was
longer in the LAC group (230 min) than in the OC group
(165 min; p = 0.012), and the median operative time in
patients with stage III disease was also longer in the LAC
group (245 min) than in the OC group (202 min;
p = 0.038) with stage III. In patients with stage II disease,
the median blood loss was signiﬁcantly lower in the LAC
group (10 ml) than in the OC group (100 ml; p\0.001),
and in patients with stage III disease, the median blood loss
was also signiﬁcantly lower in the LAC group (10 ml) than
in the OC group (155 ml; p\0.001). The duration until
start of solid food after surgery was shorter in the LAC
group (5 days) than in the OC group (7 days; p = 0.026) in
patients with stage II disease and was also shorter in the
LAC group (4 days) than in the OC group (7 days;
p\0.001) in patients with stage III disease. The median
hospital stay after surgery was shorter in the LAC group
(15 days) than in the OC group (29 days; p\0.001) in
patients with stage II disease and was also shorter in the
LAC group (7 days) than in the OC group (31 days;
p\0.001) in patients with stage III disease.
Table 4 summarizes the mortality and morbidity in each
group. There were no perioperative deaths in patients with
stage II disease. In patients with stage III disease, two
patients died postoperatively: one from severe sepsis and
septic shock in the LAC group, and one from liver failure
with liver cirrhosis in the OC group. There was no sig-
niﬁcant difference in morbidity when comparing groups.
Table 5 summarizes the oncologic outcomes for the
various groups. For patients with stage II disease, the
median (range) follow-up period was 64 (10–154) months
in the OC group and was 61 (12–128) months in the LAC
group. For patients with stage III, the median (range) fol-
low-up period was 53 (24–167) months in the OC group
and 44 (9–145) months in the LAC group.
The 5-year overall and disease-free survival rates in
patients with stage II disease were 84.9% and 84.9% in the
OC group and 93.7% and 90.0% in the LAC group,
respectively (Fig. 1A, B). The 5-year overall and disease-
free survival rates in patients with stage III disease were
63.4% and 54.6% in the OC group and 66.7% and 56.9% in
the LAC group, respectively (Fig. 2A, B). The number of
recurrences did not differ signiﬁcantly between the LAC
group and the OC group (2 versus 0; p = 0.322) in patients
Table 1 Characteristics of patients (n = 245) with transverse or
descending colon cancer
OC (n = 45) LAC
(n = 200)
p value
a
Gender (male/female) 26:19 110:90 0.734
b
Age, years (mean, range) 64 (29–84) 65 (24–90) 0.570
BMI, kg/m
2
(mean, range)
21 (16–34) 22 (16–32) 0.102
ASA classiﬁcation 0.034
b
I1 5 7 0
II 20 116
III 7 14
IV 2 0
Tumor classiﬁcation \0.001
b
02 2 0
I2 6 5
II 15 55
III 19 44
IV 7 16
OC Conventional open surgery, LAC laparoscopic surgery, BMI body
mass index, ASA American Society of Anesthesiologists
Clinical stage is classiﬁed by UICC-7 staging
a Student’s t test
b v
2 test
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123with stage II disease or between the LAC group and the OC
group (11 versus 7; p = 0.346) in patients with stage III
disease. There was no port-site recurrence or wound
recurrence in either group, and there was no signiﬁcant
difference in the site of recurrence when comparing the
groups.
Table 2 Patient demographics and characteristics of transverse and descending colon cancer in patients with stage II or stage III disease
Stage II Stage III
OC (15) LAC (55) p value
b OC (19) LAC (44) p value
b
Gender (male/female) 9:6 27:28 0.452
c 9:10 22:22 0.848
c
Age, years
a 67 (51–84) 66 (24–90) 0.654 63 (29–81) 65 (44–83) 0.701
BMI, kg/m
2a 21 (16–26) 22 (16–32) 0.975 22 (16–29) 21 (16–32) 0.528
ASA classiﬁcation 0.353
c 0.470
c
I 5 22 7 18
II 8 29 10 23
III 1 4 1 3
IV 1 0 1 0
Tumor size, cm
a 5.4 (2.5–7.6) 4.8 (1.4–8.7) 0.316 5.0 (3.2–11.2) 4.2 (1.0–10) 0.119
Lymph nodes
a 19 (7–27) 15 (3–33) 0.132 14 (5–41) 16 (5–35) 0.711
pT category 0.860
c 0.008
c
T1 0 0 0 2
T2 0 0 1 5
T3 14 52 14 37
T4 1 3 4 0
pN category – 0.566
c
N0 15 55 0 0
N1 0 0 17 37
N2 0 0 2 7
Tumor differentiation 0.071
c 0.098
c
Well 8 37 9 18
Moderate 5 17 7 25
Poor 2 0 3 1
Mucinous 0 1 0 0
Clinical stage is classiﬁed by UICC-7 staging
OC Conventional open surgery, LAC laparoscopic surgery, BMI body mass index, ASA American Society of Anesthesiologists, Well well-
differentiated adenocarcinoma, Moderate moderately differentiated adenocarcinoma, Poor poorly differentiated adenocarcinoma, Mucinous
mucinous adenocarcinoma
Lymph nodes is number of lymph nodes removed
a Values expressed as median (range)
b Mann–Whitney U test
c v
2 test
Table 3 Intraoperative and postoperative results of surgeries for transverse or descending colon cancer
Stage II Stage III
OC (15) LAC (55) p value
a OC (19) LAC (44) p value
a
Operative time (min) 165 (130–460) 230 (130–525) 0.012 202 (105–305) 245 (150–465) 0.038
Blood loss (ml) 100 (40–660) 10 (10–1050) \0.001 155 (10–660) 10 (10–450) \0.001
Days to diet 7 (5–34) 5 (2–22) 0.026 7 (4–34) 4 (3–36) \0.001
Hospital stay (day) 29 (12–72) 15 (8–53) \0.001 31 (10–75) 7 (14–156) \0.001
OC Conventional open surgery, LAC laparoscopic surgery
Values expressed as median (range)
a Mann–Whitney U test
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123Discussion
Several randomized controlled trials have demonstrated
that laparoscopic surgery for colon cancer (excluding those
with transverse or descending colon cancer) can achieve
favorable short-term outcomes and oncologic outcomes
that are similar to open surgery [5–13]. Other recent studies
of laparoscopic surgery have also demonstrated the feasi-
bility and safety of the procedure for transverse and
descending colon cancers [15–19]. However, the oncologic
outcomes of patients undergoing laparoscopic resection of
transverse and descending colon cancer have not yet been
studied.
Certainly, there are some difﬁculties when utilizing
laparoscopic resection for transverse and descending colon
cancer, as described in previous studies [15–19]; for
example, mobilization, extent of resection, and details of
lymphadenectomy may vary according to the precise
location of the tumor in patients with transverse and
descending colon cancer. In addition, resection of trans-
verse and descending colon cancers that are adjacent to
other critical structures, including the pancreas, duodenum,
spleen, and the base of the mesenteric vessels, can result in
major complications in case of dissection in the wrong
plane. Therefore, thorough appreciation of the intricacies
of venous anatomy at the gastrocolic trunk of Henle at the
level of pancreas along the right plane is required when
conducting this procedure. Jamali et al. [14] reported that a
high-grade technique was required for splenic ﬂexure
mobilization, because of the requirement for extensive
posterior dissection with simultaneous preservation of the
vascular supply to the hind gut via the marginal artery as
well as preservation of retroperitoneal structures, such as
Table 4 Mortality and morbidity associated with surgery for trans-
verse or descending colon cancer
Stage II Stage III
OC
(15)
LAC
(55)
p value
a OC
(19)
LAC
(44)
p value
a
Mortality 0 0 – 1 1 0.517
Morbidity 5 11 0.069 6 7 0.163
SSI 2 8 2 6
Leakage 1 1 2 1
Ileus 2 0 1 0
Colitis 0 2 0 0
Duodenal
ulcer
00 1 0
OC conventional open surgery, LAC laparoscopic surgery, Mortality
within 30 days after surgery, SSI surgical-site infection
a v
2 test
Table 5 Five-year oncologic outcomes of patients who underwent
surgery for transverse or descending colon cancer
Stage II Stage III
OC
(15)
LAC
(55)
p value
a OC
(19)
LAC
(44)
p value
a
Overall
survival (%)
84.9 93.7 0.240 63.4 66.7 0.819
Disease-free
survival (%)
84.9 90.0 0.489 54.6 56.9 0.890
Recurrence rate
(%)
0 3.6 0.322
b 37 25 0.346
b
Recurrence site 0 2 – 7 11 0.432
b
Liver 0 0 2 7
Lung 0 1 2 1
Local 0 1 3 3
OC conventional open surgery, LAC laparoscopic surgery, Recur-
rence site site of ﬁrst recurrence
a Log-rank statistics
b v
2 test
Fig. 1 Kaplan–Meier curves of patients with stage II disease
undergoing laparoscopic surgery or conventional open surgery:
A overall survival rate and B disease-free survival rate. There was
no statistically signiﬁcant difference in survival between the two
groups
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123the ureters and the tail of pancreas. Further, surgeons may
have comparatively less experience in dealing with this
procedure because the incidence of transverse and
descending colon cancer is low. Thus, laparoscopic trans-
verse colectomy and left colectomy are more difﬁcult than
sigmoid colectomy and right colectomy, which often limits
their use for cancers of the transverse and descending
colon, especially for those with advanced cancer. In our
institution, laparoscopic surgery has been utilized in more
than 200 patients with transverse and descending colon
cancer. The present study characterized the short-term
outcomes and oncologic long-term outcomes after resec-
tion for advanced cancer of transverse and descending
colon in patients with stage II or stage III disease under-
going OC or LAC. Gender, age, BMI, ASA, and tumor size
were similar in both groups. Operative time was longer in
the LAC group than in the OC group, likely because of
anatomical and technical difﬁculties. However, blood loss
was signiﬁcantly lower and the postoperative course of
recovery was signiﬁcantly shorter in the LAC group than in
the OC group. The morbidity and mortality were not
signiﬁcantly different when comparing the two groups.
Further, the number of dissected lymph nodes and the
incidence of intraoperative injury were not signiﬁcantly
different when comparing the two groups, nor were there
differences in the number of recurrences, overall survival,
or disease-free survival. These data indicate that laparo-
scopic surgery for advanced transverse and descending
colon cancer resulted in favorable short-term outcomes
(i.e., lower blood loss, shorter postoperative stay) and
similar oncologic long-term outcomes when compared
with conventional open surgery. Thus, laparoscopic sur-
gery is an acceptable management strategy for advanced
colon cancer regardless of tumor location.
Successful laparoscopic surgery for transverse and
descending colon cancer requires an advanced technique.
Thus, acquisition of general laparoscopic skills is required
to perform this fairly complex procedure. Since the number
of patients requiring this speciﬁc procedure is relatively
low, one way to gain this experience is through the
development of laparoscopic skills when performing sim-
pler, more common procedures, such as sigmoid colectomy
and right colectomy. This experience may attenuate the
otherwise steep learning curve needed to successfully
achieve more complex laparoscopic procedures, thereby
reducing the operative time, need for conversion to open
procedures, and complication rate.
In conclusion, laparoscopic resection for transverse and
descending colon cancer appears safe and feasible and
produces acceptable short-term and oncologic long-term
outcomes. Curative resection for advanced transverse and
descending colon cancer is technically possible; however,
the present data were derived from single-institution
experience and were not generated in a prospective man-
ner. Laparoscopic surgery for colon cancer has not yet
replaced conventional open surgery as the standard, mainly
because there is insufﬁcient clinical evidence. Further,
there are also controversies regarding the level of difﬁculty
of the individual procedure, the lack of data regarding
oncological long-term outcomes after curative resection,
and hospital costs. However, the favorable results seen in
several randomized controlled trials of the safety and
oncologic efﬁcacy of this procedure for advanced colon
cancer have resulted in increased utilization of the proce-
dure. Conﬁrmation of the value of laparoscopic surgery for
colon cancer in prospective randomized controlled trials
may result in increased demand for laparoscopic proce-
dures from physicians and patients. In our institution, the
chief and senior surgeons are actively trained in laparo-
scopic colon surgery. Indeed, with standardization of the
surgical system and gradual expansion of the indications,
more than 90% of colon surgeries in 2010 were performed
laparoscopically at our institution. Since the demand for
laparoscopic surgery for colon cancer is expected to
Fig. 2 Kaplan–Meier curves of patients with stage II disease
undergoing laparoscopic surgery or conventional open surgery:
A overall survival rate and B disease-free survival rate. There was
no statistically signiﬁcant difference in survival between the two
groups
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geons starting will gradually increase. Regardless, we
believe that laparoscopic surgery may become the gold
standard for management of colon cancer, regardless of
stage or tumor location.
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